Shares of Myriad Genetics (MYGN) rose 14.6% to $21.40 in early trading on Wednesday. The Salt Lake City-based firm after the market close on Tuesday reported fiscal third quarter 2017 results that topped analysts' expectations.

Myriad reported adjusted earnings per share of $0.27 on revenue of $196.9 million. Analysts had forecast adjusted EPS of $0.23 on revenue of $189.1 million, according to FactSet Research Systems.

For fiscal year 2017, the company raised its revenue guidance to $763 million to $765 million from the previous range of $745 million to $755 million. Myriad narrowed its adjusted EPS guidance to $1.01 to $1.03 from the prior guidance of $1.00 to $1.05.

Shares of Spectrum Pharmaceuticals (SPPI) were down 6.1% to $7.07. The Henderson, Nev.-based firm after the market close on Tuesday reported first-quarter non-GAAP net loss of $11.4 million, or $0.14 per basic and diluted share, compared with non-GAAP net income $0.3 million, or $0.01 per basic share and less than $0.01 per diluted share, in the same period in 2016. Revenue was $29.1 million, versus $43.87 million in the year-ago period.

Among the other biotech movers was Array BioPharma (ARRY) , up 8.6% to $7.99.

More from Health

How to Invest in Cannabis - In Its Many Forms

How to Invest in Cannabis - In Its Many Forms

Eli Lilly, AstraZeneca Shares Fall After Halting Alzheimer's Drug Test

Eli Lilly, AstraZeneca Shares Fall After Halting Alzheimer's Drug Test

There's Nothing Funny About Guardianship

There's Nothing Funny About Guardianship

White House Economic Adviser Larry Kudlow in Good Condition After Heart Attack

White House Economic Adviser Larry Kudlow in Good Condition After Heart Attack

Can Legal Cannabis Help Slow the Opioid Drug Epidemic in the U.S.?

Can Legal Cannabis Help Slow the Opioid Drug Epidemic in the U.S.?